Sotera Health reports 9.1% revenue growth and 12.2% EBITDA increase, reaffirming guidance while addressing litigation updates.

Good morning and welcome to the Sotera Health third quarter 2025 conference call. All participants will be in a listen only mode. Should you need assistance, please signal a conference specialist by pressing the Star key followed by zero. After today's presentation there will be an opportunity to ask questions. To ask a question you may press star then one on a touch tone phone. To withdraw from the question queue, please press Star and then two. Please note this event is being recorded. I would now like to turn the conference over to Vice President of Investor Relations Jason Peterson. Jason please go ahead Good morning and thank you. Welcome to Sotera Health's third quarter 2025 earnings call. You can find today's press release and accompanying supplemental slides on the Investor section of our website@soterahealth.com this webcast is being recorded and a replay will be available in the Investors section of the Sotera Health website. On the call with me today are Chairman and Chief Executive Officer Michael Petras and Chief Financial Officer John Lyons. During the call, some of our comments may be considered forward looking statements. The matters addressed in these statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to Sotera Health's SEC filings in the forward looking statement slide at the beginning of the presentation for a description of these risks and uncertainties. The Company assumes no obligation to update any such forward looking statements. Please note that during the discussion today the Company will present both GAAP and non GAAP financial measures including adjusted ebitda, adjusted EBITDA margin tax rate applicable to net income, adjusted net Income, adjusted eps, net debt and net leverage ratio in addition to constant currency comparisons. A reconciliation of GAAP to non GAAP measures for all relevant periods may be found in the schedules attached to the Company's press release and in the supplemental slides to this presentation. The operator will be assisting with the Q and A portion of the call today. Please limit yourself to one question and one follow up so that we can give everyone an opportunity to ask questions. If you have any questions after the call, please feel free to reach out to me and the Investor Relations team. I will now call Turn the call over to Sotera Health Chairman and CEO Michael Petras.

Good morning and thank you for joining us today. I'm pleased to report another excellent quarter for Sotera Health marked by strong top line growth, double digit adjusted EBITDA growth, margin expansion of approximately 150 basis points and a 9 cent adjusted EPS increase compared to the third quarter of 2024. Total company revenues increased 9.1% for the quarter while adjusted EBITDA increased 12.2%. Sterigenics delivered another strong quarter, achieving 9.8% top line growth compared to the third quarter 2024 driven by consistent performance across. Our core medical device customers. Norion delivered revenue growth of 22.4% which was primarily driven by the timing of the reactor harvest schedules versus the third quarter of 2024. Revenue was ahead of our expectations as certain customer deliveries originally scheduled for the fourth quarter were fulfilled in the third. Quarter, while Nelson Labs delivered third quarter. Revenue that was modestly below our expectations. Our growth in core lab testing and operational improvements drove segment income growth and margin expansion. This marks the fifth consecutive quarter of. Year over year margin expansion in Nelson. Labs, highlighting our focus on execution. In addition to our strong performance during. The quarter, we strengthened our balance sheet. Through paying down $75 million of debt and lowered our interest expense by approximately $13 million annually. John will elaborate more on this shortly. Given our strong year to date results. And visibility in the remainder of the year, we are reaffirming our 2025 revenue outlook and are raising our adjusted EBITDA. Outlook each quarter I have emphasized Sotera. Health's vital role in global healthcare I'm pleased to share that Nordeon recently secured a 25 year renewal of its Class 1B operating license, the longest Class 1B license ever granted by the Canadian Nuclear Safety Commission. This milestone reflects our deep trusted partnership with the CNSC and their confidence in Nordon's safety, culture and operational excellence. With this renewed license, Nordion will continue to secure the global supply of cobalt 60, supporting critical sterilization processes including those performed by Sterigenics and enabling life saving radiotherapeutic treatments for brain tumors and early stage breast cancer. This achievement reinforces our mission of safeguarding global health by ensuring a reliable supply of critical cobalt 60 for our customers, the health care system and patients for decades to come. Now I'll turn over to John who.

Will walk us through the financials. Thank you, Michael. I'll start with a review of our consolidated third quarter 2025 results followed by a breakdown of performance across each business segment on a consolidated basis. Third quarter revenues increased 9.1% to $311 million or 8% on a constant currency basis as compared to the third quarter of 2024. Adjusted EBITDA increased by 12.2% to $164 million or 11.2% on a constant currency basis versus the third quarter of 2024 Adjusted EBITDA margins reached 52.7%, an increase of 147 basis points over the prior year driven by improved margins in both Stereogenics and Nelson Labs. Interest expense for the third quarter was $39 million, an improvement of approximately $2.4 million versus the same period last year. Net income for Q3 2025 was $48 million or $0.17 per diluted share compared to net income of $17 million or $0.06 per diluted share in Q3 2024. Adjusted EPS was $0.26, an increase of $0.09 from the third quarter of 2024. Nearly $0.04 of this benefit came from adjusted EBITDA growth. Less than $0.01 came from lower interest expense, while the remainder relates to a reduced tax rate. Now let's take a closer look at our segment performances. Sterigenics continued its strong performance in the third quarter, delivering 9.8% revenue growth to $193 million or 8.4% on a constant currency basis compared to Q3 2024. The revenue growth was driven by favorable volume mix of approximately 4.6%, increased pricing of 3.8% and 140 basis point benefit from foreign currency exchange. Segment income increased 11.6% to $107 million or 10.2% on a constant currency basis with margins improving 90 basis points year over year at 55.6% driven by strong top line growth partially offset by inflation. Nordion's third quarter revenue increased 22.4% to $63 million or 23.6% on a constant currency basis compared to Q3 of 2024. Nordion's revenue increase was driven by a vitamin mix benefit of 18.9% and favorable pricing of 4.7%, partially offset by an unfavorable impact of 120 basis points from changes in foreign currency exchange rates. Nordion's Segment income increased 19.9% to approximately $38 million or 21.2% on a constant currency basis versus Q3 of 2024. Segment income growth was driven by increased volume and mix as well as customer pricing. Segment income margin was 60.6% reflecting a decrease of approximately 130 basis points driven by product mix. On a year to date basis, Nordion segment income margins have increased more than 70 basis points. Nelson Labs reported third quarter 2025 revenue of $56 million, a 5% decline compared to the same period last year. Favorable contributions from pricing of 2.7%, foreign exchange of 1.4% and core lab testing growth were offset by the decline in expert advisory services. Nelson Labs third quarter 2025 segment income rose 1.9% to $19 million or flat on a constant currency basis, with margins expanding 229 basis points year over year to 34.1%. Segment income and margin improvement were driven by volume and mix improvements, lab optimization and favorable pricing. Let's now turn to our balance sheet cash generation and capital deployment activities. Year to date we have generated $184 million in positive operating cash flow while capital expenditures totaled $87 million. The company continues to be in a very strong liquidity position. As of the end of the third quarter we had over $890 million of available liquidity which included almost $300 million in unrestricted cash and nearly $600 million of available capacity on a revolving line of credit. We continue making progress toward our long term net leverage target range of 2 to 3 times. Our net leverage ratio improved to 3.3 times at quarter end, down from 3.7 times at the end of 2024 and down from 4.2x as of Q3 2023. As Michael mentioned, we took strategic actions this quarter to strengthen our balance sheet and lower interest expense. First, continued adjusted EBITDA growth and cash generation helped us achieve a contractual net leverage target, triggering a 25 basis point reduction in our term loan interest rate. Then in September we repriced the term loan for an additional 50 basis point reduction and repaid $75 million of the facility. These steps are expected to generate approximately $13 million in annual interest savings. Now I'd like to turn to our 2025 full year outlook. We are maintaining our full year constant currency revenue growth outlook range of 4.5 to 6% and anticipate revenue growth will land near the midpoint of this range with continued benefits from volume growth and operational improvements. We are raising our constant currency adjusted EBITDA growth outlook to 6.75% to 7.75%, up from the prior range of 6 to 7.5%. Foreign currency is expected to contribute approximately 25 basis points to revenue and adjusted EBITDA growth versus the prior outlook of no impact. Total company price for 2025 is still expected to be near the midpoint of our long term stated range of 3% to 4%. For stereogenics, we continue to expect 2025 constant currency revenue growth of mid to high single digits. For Nordeon, we've raised Our full year 2025 constant currency revenue growth outlook and now expect mid to high single digit growth Additionally, I'm pleased to report that for 2025 there is no longer any revenue risk associated with Cobalt 60 for Nelson Labs. We now expect full year 2025 constant currency revenues to decline mid single digits as the impact from expert advisory services more than offsets the continued growth in core lab testing and improved pricing. We expect segment income margin to finish in the low to mid-30s percent range for the full year. Turning to other guidance items driven by our balance sheet initiatives discussed earlier, we are improving our interest expense range to $154 million to $158 million from our previous outlook of $155 million to $165 million. Our effective tax rate on our adjusted net income is expected to be in the range of 29% to 31%, improving from the prior range of 31.5 to 33.5%. The lower tax rate on adjusted net income reflects the adoption of recent accounting guidance related to the US Tax law changes enacted in July. We now expect adjusted EPS to be in the range of 81 to 86 cents, an increase in the previous range of 75 to 82 cents. The 5 cents improvement from the midpoint of the prior eps range reflects $0.02 driven by incremental EBITDA generation and reduced interest expense, with the balance driven by the favorable tax rate change. We expect the fully diluted share count to remain in the range of 286 million to 287 million shares. We now expect capital expenditures to be in the range of $125 million to $135 million, below our prior outlook of 170 to $180 million, driven by Project timing and incremental cost savings. While spending cadence has shifted, our expectation for cumulative capital expenditures from 2025 through 2027 remains unchanged and we are on track to achieve our $500 to $600 million cumulative free cash flow commitment provided our 2024 Investor Day. We continue to expect year end 2025 net leverage ratio to improve compared to 2024. Finally, as usual, our outlook does not assume any MA activity. I'll now turn the call back over to Michael.

Thank you, John. We're very pleased with the quarter's performance. I would now like to give an update regarding the ethylene oxide EO personal injury claims in Cobb County, Georgia. Although this is a lengthy and detailed update, the key point is while the cases pending in Cobb county still have a ways to go, we believe the recent Phase one and Phase two rulings align with our long Standing position that when science is considered fully, fairly and properly, the evidence refutes the plaintiff's claims in these matters. As a reminder, the Cobb county court ordered phase proceedings in eight bellwether cases selected by the plaintiff's counsel. Phase one was devoted to general causation. The court required the plaintiffs to prove that EO admissions from our Atlantic facility are capable of causing the diseases alleged by the plaintiffs. In November 2024, the court excluded two of the plaintiffs, three general causation experts, but allowed the third expert under a quote, new standard, end of quote, created by the court for these cases that did not require the plaintiffs to establish the exposure levels at which EO becomes harmful to humans. Both sides appealed. On Friday, October 31, the Georgia Court of appeals rejected the trial court's new standard, end of quote, and vacated the trial court's phase one orders. Consistent with our position, the court of appeals directed the trial court to apply the correct standard that requires causation experts to reliably identify the levels at which exposure to EO becomes harmful. The court of appeals also instructed the trial court to consider whether plaintiffs can prove general causation using epidemiologic evidence and background risk of the diseases at issue, which all occur in the general population without exposure to EO emissions. While the phase one appeals were pending, three of the bellwether cases proceeded to phase two, which was devoted to specific causation. Plaintiffs were required to present admissible expert testimony that the plaintiffs were exposed to doses of EO from the Atlanta facility that caused their diseases. On October 17, the trial court excluded all three of the plaintiff's causation experts and and dismissed all three cases for failure to present reliable and admissible evidence of specific causation. The court also dismissed the plaintiffs claims for nuisance, noting that the plaintiffs had not presented any evidence that the Atlanta facility had violated EPA, GA, EPD or Cobb county requirements. Although the phase two orders apply only to three bellwether cases, we believe the substantive grounds for the rulings apply with equal force to the remaining personal injury claims. This will be decided in due course by the Cobb county court and if necessary, the Georgia appellate courts. We will continue to put the science front and center as we defend Sterogenics Safe and essential operations. This statement, the trial court's phase one and phase two orders, and the decision of the Georgia court of appeals are all available on our website at this point. Operator, I'd like to open it up for questions and answers.

Thank you. We will now begin the question and answer session to ask a Question, you may press star then one on your touchtone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw from the question queue, please Press Star Then 2. At this time, we will pause momentarily to assemble our roster. And your first question today will come from Patrick Donnelly with Citi. Please go ahead.

Hey, great. Thanks for the question. Maybe just one on the volume recovery. Nice to see that continue. Are there certain areas you guys are seeing kind of outsized recovery? I think last quarter you talked a little bit about medtech and bioproduction. Maybe what you're seeing there and what the expectations on the volume trajectory are from here.

Hey, Patrick. Good morning. This is Michael. We're seeing pretty consistent performance across sterogenics and across multiple, almost all categories, bioprocessing, med tech, broadly. Overall, we're seeing good recovery in volumes, and we expect that to continue going forward.

Okay, great. And then just a quick one helpful on the litigation update there. I guess maybe a quick one just in terms of where some of the other cases are. Again, it sounds like we can continue to see some of these updates, but we'd love to just hear the latest on the broad litigation side and how you're feeling on that front.

Yeah, Patrick, you know, Illinois is, you know, wrapping up. We've got the April 2025 settlement that we did that's been completed. And close out the July 25th one is progressing well. That will leave us with only one remaining case in Illinois, in Georgia. I just gave you a lengthy update there on New Mexico. Right now, there's no personal injury claims currently, and there's only one suit brought by the AG for public nuisance that's set for trial in July 2026. And then in California, we've recently been informed that the first trials are expected in January and April of 2027.

All right, perfect. Thanks, Michael.

Thank you. Your next question today will come from Casey Woodring with JP Morgan. Please go ahead.

Hi, this is Jayden Onford. Casey, thank you so much for taking my question. Just first on stereogenics, I was just wondering, are you factoring any expectation of budget flush in 4Q? And given you've reaffirmed your revenue outlook for the year after year three Q beat, can you touch on how conservative your guidance is for 25 and the puts and takes behind that? Thank you.

I'm sorry, can you repeat the question on sterogenics? I wasn't sure I understood that first question.

I was just wondering if you were factoring in any expectation of a budget flush in 4Q.

Budget flush. Are you talking about the government shutdown? Is that what you're referencing when you say budget flush?

No, I'm talking from the Medtech customers from Medtech or Bio Processing.

We're not expecting a budget flush. No. And when I look forward, you know, we feel confident of our guidance and outlook that we're giving you here for the rest of the year. I wouldn't say it's aggressive. I wouldn't say it's conservative. We just feel confident where it is with one core to go.

Okay, got it. And then just to follow up just on that government shutdown, since you mentioned it, are you seeing any impact from that in your RCA business or anywhere across your portfolio?

When we look at, remember, we have no direct government sales in the business, there's some indirect impact, but it's pretty minimal. It's not a material impact. We do feel a little bit of it in the expert advisory services with some of the delays going on and activity there's. But overall we don't see a material impact to the company. We do not have direct sales to the government.

All right, got it. Thank you.

Your next question today will come from Luke Surgott with Barclays. Please go ahead. Great.

Thanks for the question. Just two for me is about the one on the expert advisory business. It seems to have gotten worse here. Is that just related to the lack of FDA funding, lack of inspections and kind of the government shutdown. And then the second one is on the implied 4Q EBITDA margin, step down. Just want to know what's going on there. And I assume it's probably just not the Nordeon volumes, but just wanted to see if anything else going on.

Yeah. Good morning, Luke. Yeah, I would say expert advisory services in that RCA business is feeling some of the impact from the FDA lack of activity. So that's clearly impacting. It was worse than we expected. But overall it's had a material impact on the top line for the company. It's about 10 points of impact. John is at roughly about 10 point of impact on the top line. But overall the core lab testing is improving, which is what we had hoped for and we're continuing to see. John, you want to address the margin question that Luke had as well? Yeah.

Luke, as we look at the margins in Q4, we anticipate that Nelson will step back a bit from where they are at this peak in Q3. Q3 had the benefit of some pretty. Low expenses inside of that. And then we've been running really well. In steri we could see a little bit of step back in that, but nothing alarming there. Still stable margins for the year, maybe even slight growth for the year for stereogenics.

Okay, great, thanks.

Your next question today will come from Dave Windley with Jefferies. Please go ahead.

Hi, good morning.

Thanks for taking my questions. Maybe follow up on Nelson and ask the, I guess the other side of the coin, Michael, the core lab testing and the pickup there. So just kind of thinking about the balance if expert advisory is feeling this headwind and you know, that's kind of prisoner to what the government does on funding an fda. What does the rest of the business look like and what's the demand quotient there? Yeah, thanks, David. I'd say overall core lab testing is doing pretty well. We'd like to continue to see more growth. The routine volumes or some of the flow volumes are picking up like we see in the sterilization volumes. Validation has been a little bit choppy, but we got some pockets, particularly with some of the new regulations. You know, some of the requirements of extractable, leachable testing and bioprocessing components and things of that nature are all doing well. So overall we're seeing some nice growth in the lab testing core. We'd like to see it better, but overall it's going the right direction. And you know, fundamentally we're seeing the embedded labs growth continue. The linkage with the stereogenics piece and the volumes there are clearly having an impact in a positive way.

Got it. And then maybe zooming out a little bit and just thinking more broadly to the question on kind of the fourth quarter sequential progression. I think as Luke highlighted, there's a little bit of margin pullback. John, you addressed that. The revenue growth indicated by your guidance also steps back a little bit. And so I wondered if you could just comment on, on cadence timing, you know, things that for the year were reflected in 3Q that you maybe thought were going to land in 4Q, that kind of thing relative to, you know, kind of trajectory, what's the smooth trajectory that fits through what is a higher 3Q and a lower 4Q? Thanks.

Yeah, thanks, David. I would just say, you know, we talked about the Nelson comments and the things that we're seeing on expert Advisory Service. The other big factor that we talked about last quarter, we're reentering today is the Nordeon. The Nordeon lumpiness. We said it was going to be down significantly versus last year fourth quarter. And that's what you're referencing. That's the piece. So we had a Portion of it as we referenced in our comments here that pulled into the third quarter from customers request. But overall we still expect it to be down significant from last year, all due to timing. But overall, when you look at the total year for Nordeon, it'll be actually above our expectations as we also commented on here today. So I think that's the other piece.

Okay, great, thanks.

Question will come from Brett Fishbin with KeyBank. Please go ahead.

Hey guys, good morning. Thank you so much for taking the questions. Just had a quick one on Nordeon. You know, notice the very strong revenue growth in the quarter in excess of 22%. But I think you noted that there was some margin pressure from the mix and was just curious, kind of like what type of mix shift with Nordeon was causing some margin compression and does that persist moving forward?

Hey Brett, it's Michael here. So you look at the business, it's tough to talk about margin pressure in the Nordium business when you see the margins that we put up in that business. What we're referencing there is product sales in particular production of radiators, equipment sales. That's a lower margin and we saw some growth in that in the quarter. We'll see that sporadically here and there, but we don't see that as a material impact long term. The margin rates continue to be very strong in that business, as you know.

That is a very fair point. And then just on Sterogenics, it was really great to see a second quarter of really improved trends for the segment. I was just curious how you think about overall sustainability of call it mid to high single digit or high single digit type of growth as we look ahead into 2026 and maybe short of giving guidance if there's any key moving pieces that you would call out for next year other than potentially more challenging comparisons. Thanks again.

Yeah, great. Listen, we're proud of what the Stereogenics team is. They're executing very well. We set our long range guide there would be mid single digits to high single digits. We're reiterating that and I would just say, you know, overall, you know, we'll give guidance when we give, you know, guidance at the beginning of next year. But overall, when we look at our long range commitments we made in the investor day last November, we still feel pretty confident around that. So we're well situated. We'll talk about 26 when we get there.

The next question will come from Jason Bednar with Piper Sandler. Please go ahead.

Hey, good morning guys. Thanks for taking the questions and congrats on the quarter here, I wanted to first start on stereogenics pricing. It decelerated ever so slightly. I know we're talking tens of basis points on a sequential basis, but I think you've been trending down 50 to 60 basis points year on year the last few quarters. I think this is also the smallest pricing tailwind we've seen in at least a few years. And look, it's still good. It's better than a lot of other healthcare verticals. But where do you think this pricing contribution stabilizes? Is this the level? Do we need to drift lower? And then maybe the follow up there would be. I think you've talked in the past about stronger opportunities in pricing and stereogenics in light of the investments you've been making in your facilities. Is that potentially a reversal of sorts as we think about pricing going forward for stereogenics?

Yeah, thanks, Jason. We said last year, November, we talked about price across the company, 3% to 4%. We said SterijenX would be the high end of that range. And that's basically where they're coming in at. We see that continuing. We don't see any concern around that. If it's 3.8, 3.94, it's right in that neighborhood. We see that we can't call it that closely, but we also look at some of the ne shap opportunities and those are things that we would say that could come on top of that over time as we roll out that program and the regulations get set in the marketplace. So that would be above that run rate.

Okay. And maybe just to follow up on that last point, Michael, is that as you referenced that opportunity over time, is that more of a like post 26, not asking for 26 guidance, but is that a post 26 comment? Knowing that, you know, you know, your compliance with Neshap is still going to, you know, still a few quarters out. And then separately appreciate everything that you gave us on the litigation update side, especially on all the detail around Georgia. We'll get the details when the queue is filed. But can you update us on the number of cases in California? I don't think we heard that other than just the start of some of those case dates.

Yeah, I'm sorry, I was getting distracted by your second part. What was the first part of the question, Jason? Again, post 26. Oh, post 26 on the niche app. I'm sorry. Thank you. I had a little hesitation there. I would just say we're working with our customers on the appropriate way to price in the capital improvements. We Put in our facilities, that'll build out over time. Yes, the ESHAP timeline has been pushed out a little bit, so we're working with our customers to do that. But you'll see a gradual improvement for that incremental price over time. Again, to your point, we don't want to get into 2026, but we'll give you some proper guidance on that for 26 and 27 and 28 as we look at that pricing on Neshap. As far as California, there's 83 personal injury claims.

All right, perfect. Thanks so much, guys.

Thank you. And your next question today will come from Michael Pollark with Wolff Research. Please go ahead.

Hi, good morning, Nelson. If I'm doing the math for 4q maybe in constant currency terms flattish year on year, obviously the comp gets easier as we lap in this advisory services headwind. My question is for 26 and I'm not asking for formal guidance, but with this big advisory headwind now in, is it reasonable to expect, given what you're seeing on routine testing, to expect Nelson to return to growth in 26?

Yeah. Yeah, that's a logical conclusion, Mike. We're not getting into 26 guidance, but you're thinking about the right way.

My follow up on Sterogenics last quarter, after your clear acceleration and a good number from your competitor, the discussion was around order patterns ahead of tariffs. And so I'm curious, three to six months later, do you have any better feel for whether in the second or third quarters there was maybe a little bit of extra pull forward of ordering from Medtech customers as they maneuvered supply chains ahead of Trump tariffs?

Yeah, you know, we, you know, we, as I mentioned in the past, we have a pretty rigorous process in doing commercial reviews and volume reviews with the team and we're seeing very minimal impact from that. I mean, there's. The only reason I'd even tell you any is because, you know, we had a couple facilities. As we look back on it, there were some stat fees that came in with some last minute requirements from customers, but nothing material. When you look at the overall scale of the business doing approximately $300 million of revenue per quarter across the company in total, or $197 million in stereogenics. There's nothing material there that we're able to see.

Thank you, Michael.

This concludes our question and answer session. I would like to turn the conference back over to Michael Petras for closing remarks.

Great, thank you. We achieved excellent results again this quarter with solid revenue growth, margin expansion and improved financial strength. Right. We're built for resilience and sustainable growth. Our stable, recurring revenue base and expertise enable us to support our customers in highly regulated markets and deliver consistent results through varying economic cycles. We want to thank you to our customers and investors for your continued trust and partnership. We appreciate your support and we look forward to speaking with you again next quarter. And have a great day. Thank you.

The conference has now concluded. Thank you for attending today's presentation. Thank you. You may now disconnect.